Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Agenix Sells China Rights for Hepatitis B Treatment to Cinkate

publication date: May 20, 2014
Agenix, an Australian biopharma with a drug development subsidiary in Shanghai, sold its pre-clinical treatment for hepatitis B to Cinkate Pharmaceutical Intermediates for $2 million. The drug candidate, AGX-1009, is a prodrug of tenofovir, a nucleotide analogue reverse transcriptase inhibitor. Cinkate is a US company that is focused on drug development in China and markets Airohua® (lefluonomide) for autoimmune indications. More details....

Stock Symbol: (ASX: AGX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital